What will Johnson & Johnson say during their next earnings call?
$43,288 Vol.
Jan 21, 2026
Nipocalimab / Lupus
$339 Vol.
Oui
Nipocalimab / Lupus
$339 Vol.
Oui
Halda Therapeutics / Haida Therapeutics
$4,472 Vol.
Oui
Halda Therapeutics / Haida Therapeutics
$4,472 Vol.
Oui
Darzalex Faspro
$266 Vol.
No
Darzalex Faspro
$266 Vol.
No
Ottava
$7,631 Vol.
Yes
Ottava
$7,631 Vol.
Yes
Vaccine
$7,002 Vol.
No
Vaccine
$7,002 Vol.
No
Procedure
$665 Vol.
Yes
Procedure
$665 Vol.
Yes
Europe
$568 Vol.
Yes
Europe
$568 Vol.
Yes
Carvykti
$355 Vol.
Yes
Carvykti
$355 Vol.
Yes
Rybrevant
$2,497 Vol.
Yes
Rybrevant
$2,497 Vol.
Yes
Trufill
$2,551 Vol.
No
Trufill
$2,551 Vol.
No
Administration
$16,687 Vol.
Yes
Administration
$16,687 Vol.
Yes
China
$254 Vol.
Yes
China
$254 Vol.
Yes
Règles
This market will resolve based on the next earnings announcement of Johnson & Johnson currently scheduled to take place on January 21, 2026 at 8:30 AM EST.
This market will resolve to "Yes" if the listed term is mentioned by anyone during this event. Otherwise, the market will resolve to "No".
Any usage of the term, regardless of context, will count toward the resolution of this market.
Pluralization/possessive of the term will count toward the resolution of this market; however, other forms will NOT count.
Instances where the term is used in a compound word will count regardless of context (e.g. joyful is not a compound word for "joy," however "killjoy" is a compounding of the words "kill" and "joy").
If this market requires a specified number of mentions of a person’s first or last name, a full-name mention will count as one mention (e.g., if a market is about “Joe / Biden 5+ times,” a mention of “Joe Biden” will count once).
A Q&A event will count toward the resolution of this market.
If this event is definitely cancelled, or otherwise is not aired by March 31, 2026, 11:59 PM ET, this market will resolve to "No".
The resolution source will be audio of the event.
This market will resolve to "Yes" if the listed term is mentioned by anyone during this event. Otherwise, the market will resolve to "No".
Any usage of the term, regardless of context, will count toward the resolution of this market.
Pluralization/possessive of the term will count toward the resolution of this market; however, other forms will NOT count.
Instances where the term is used in a compound word will count regardless of context (e.g. joyful is not a compound word for "joy," however "killjoy" is a compounding of the words "kill" and "joy").
If this market requires a specified number of mentions of a person’s first or last name, a full-name mention will count as one mention (e.g., if a market is about “Joe / Biden 5+ times,” a mention of “Joe Biden” will count once).
A Q&A event will count toward the resolution of this market.
If this event is definitely cancelled, or otherwise is not aired by March 31, 2026, 11:59 PM ET, this market will resolve to "No".
The resolution source will be audio of the event.
Créé le : Jan 12, 2026, 12:39 PM ET
Volume
$43,288Date de fin
Jan 21, 2026Créé le
Jan 12, 2026, 12:39 PM ETResolver
0x65070BE91...Résultat proposé: No
Aucune contestation
Résultat final: No
What will Johnson & Johnson say during their next earnings call?
$43,288 Vol.
Nipocalimab / Lupus
$339 Vol.
Oui
Halda Therapeutics / Haida Therapeutics
$4,472 Vol.
Oui
Darzalex Faspro
$266 Vol.
No
Ottava
$7,631 Vol.
Yes
Vaccine
$7,002 Vol.
No
Procedure
$665 Vol.
Yes
Europe
$568 Vol.
Yes
Carvykti
$355 Vol.
Yes
Rybrevant
$2,497 Vol.
Yes
Trufill
$2,551 Vol.
No
Administration
$16,687 Vol.
Yes
China
$254 Vol.
Yes
À propos
Volume
$43,288Date de fin
Jan 21, 2026Créé le
Jan 12, 2026, 12:39 PM ETResolver
0x65070BE91...Méfiez-vous des liens externes.
Méfiez-vous des liens externes.

Méfiez-vous des liens externes.
Méfiez-vous des liens externes.